Skip to main content
. Author manuscript; available in PMC: 2014 Dec 23.
Published in final edited form as: ACS Nano. 2013 Nov 11;7(12):10671–10680. doi: 10.1021/nn403370e

Figure 3. Synthesis and screening of 45 NPs with different sizes and PEG coverage.

Figure 3

(A) Fluorescence intensity (FI) of macrophages associated with Alexa-488-labeled NPs. Heat map indicating extent of size, PEG weight % and average PEG length for each formulation. (B) Pharmacokinetic profile measured by the relative fluorescence of Alexa-647-labeled NPs in blood. (C) Circulation half-life and (D) area under the curve of selected formulations with increasing macrophage binding and uptake. See Table S2 for details of the NP formulations. Error bars denote ±S.D.